Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+ HER2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05297617
What this trial is testing

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

Who this might be right for
Breast Cancer
UNICANCER 696
Large-scale testing (Phase 3)Looking for participantsNCT06998108
What this trial is testing

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Who this might be right for
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
BeBetter Med Inc 330
Not applicableLooking for participantsNCT07702708
What this trial is testing

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Breast CancerBreast Neoplasms
Fujian Cancer Hospital 100
Not applicableUnknownNCT05000736
What this trial is testing

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

Who this might be right for
Hormone Receptor Positive Advanced Breast Cancer
Chinese Academy of Medical Sciences 600
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Large-scale testing (Phase 3)Looking for participantsNCT07242352
What this trial is testing

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

Who this might be right for
Breast CancerHR+/HER2- Breast Cancer
Women's Cancer Study Group GmbH 1,520
Not applicableActive Not RecruitingNCT05529862
What this trial is testing

Trans-RosaLEE Study: a Biomarker-directed, Translational Study

Who this might be right for
Advanced or Metastatic Breast Cancer (BC)
Institut Paoli-Calmettes 115
Testing effectiveness (Phase 2)Looking for participantsNCT07661927
What this trial is testing

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)
UNICANCER 700
Testing effectiveness (Phase 2)Active Not RecruitingNCT05101096
What this trial is testing

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Triple-Negative Breast CancerHR+/HER2- Metastatic Breast Cancer+1 more
Gilead Sciences 135
Large-scale testing (Phase 3)UnknownNCT05433480
What this trial is testing

BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Betta Pharmaceuticals Co., Ltd. 274
Testing effectiveness (Phase 2)UnknownNCT06000033
What this trial is testing

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Qilu Hospital of Shandong University 35
Testing effectiveness (Phase 2)Ended earlyNCT04460430
What this trial is testing

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 12
Large-scale testing (Phase 3)Looking for participantsNCT06081959
What this trial is testing

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Not applicableUnknownNCT05544123
What this trial is testing

The Treatment Situation of Chinese County Population With Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Tumor
The First Affiliated Hospital of Xinxiang Medical College 2,500
Testing effectiveness (Phase 2)Study completedNCT05159778
What this trial is testing

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Who this might be right for
Malignant Neoplasm of Breast
HiberCell, Inc. 26
Testing effectiveness (Phase 2)Looking for participantsNCT07732491
What this trial is testing

Culmerciclib in HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastastic Breast CancerHER2+ Advanced Breast Cancer
Sun Yat-sen University 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07102940
What this trial is testing

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Who this might be right for
Breast CancerHER 2 Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+1 more
George Washington University 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07300215
What this trial is testing

An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital of Bengbu Medical University 60
Not applicableLooking for participantsNCT07407439
What this trial is testing

Real-world Studies of CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 245
Not applicableLooking for participantsNCT07180056
What this trial is testing

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Wenjin Yin 229
Next Page